Post-Hoc Live

About Post-Hoc Live

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

Publisher

Endpoints News

Category

news

Language

en

Explicit

No

First episode

11 Jun 2025

Latest episode

17 Sept 2026

Latest episodes

52 episodes in the feed.

1. 

   17 Sept 2026

   Live from DC: Will Congress put a stop to China biotech deals?

   There isn't a lawmaker on Capitol Hill who's publicly taken a more conservative stance to biopharma's deal spree in China than Rep. John Moolenaar (R-MI), chairman of the House Select Committee on China. He's been the architect of recent legislative proposals that'd clamp down on deals there and also what data regulators can review. So how did this issue rise to his attention? And how committed is he to pressing the issue? Live from Endpoints’ ⁠China Biotech Debate: Washington, DC⁠ ⁠ (https://events.endpoints.news/china-biotech-dc?i=LUPF9TdpM7PAuAgIC0P4LFurdX9IosA6)on September 15, 2026.

2. 

   17 Sept 2026

   Live from DC: Is secrecy the solution?

   What do you do when you announce a drug program, then turn around and find out that there are a dozen competitors in China working on the same idea? For many US biotechs, the answer has been to hide their work as long as possible, limiting what they share with the outside world in the hope that it will keep new competitors from emerging (and passing them by). It's a tactic that's been adopted broadly in US biotech, and has led to calls for changes to the patent system. But is it a long-term solution or a short-term fix? And what are the unintended consequences of an R&D and intellectual property system that's less transparent? Live from Endpoints’ ⁠China Biotech Debate: Washington, DC⁠ ⁠ (https://events.endpoints.news/china-biotech-dc?i=LUPF9TdpM7PAuAgIC0P4LFurdX9IosA6)on September 15, 2026.

3. 

   17 Sept 2026

   Live from DC: What do we really mean when we talk about biosecurity risk and China?

   Huge genetic databases. Drug ingredient supply chains. A next pandemic. War with Taiwan. Economic competition. A huge number of topics and scenarios get lumped into the "China biosecurity" conversation — some present and real, some far-fetched and far-off. So what are we really talking about when we talk about China and bio-risk? What deserves the attention and policy action? Which ones are fear-mongering? Live from Endpoints’ ⁠China Biotech Debate: Washington, DC⁠ ⁠ (https://events.endpoints.news/china-biotech-dc?i=LUPF9TdpM7PAuAgIC0P4LFurdX9IosA6)on September 15, 2026.

Who has been a guest on Post-Hoc Live

Names identified in recent episode analyses. Showing up to five guests.

• Industry experts
• industry leaders
• Andrew Dunn
• Abhi Mahajan
• Mandy Cohen

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

YouTube views

11,517

Score snapshot 15 Sept 2025

Apple Podcasts (US)

5.0 / 5

5 ratings

Spotify

5.0 / 5

4 ratings

Podcast Authority Score: 47 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

64

Social presence

0

YouTube

76

Engagement

0

Contact Post-Hoc Live

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.

Shows with a similar audience

• 

  BioCentury This Week

• 

  The Readout Loud

• 

  Biotech Hangout

• 

  The Long Run with Luke Timmerman

• 

  Odd Lots

• 

  Economist Podcasts

Questions about Post-Hoc Live